Altimmune Dividends and Buybacks
Dividend criteria checks 0/6
Altimmune does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-14.0%
Buyback Yield
| Total Shareholder Yield | -14.0% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Regulatory And Clinical Catalysts Ahead For Altimmune
Oct 28Consider Buying Potential Takeover Target Altimmune
Oct 02Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Sep 21We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Sep 12
Altimmune: Emerging Position In Competitive Space, But Risks Remain
Aug 27Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note
Jun 24Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns
May 27Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Altimmune: Overreaction On NASH Data Creates Buying Opportunity
Sep 15Reassessing Altimmune
Sep 07Altimmune sets new 52-week high on rising volume
Aug 31Altimmune Q2 2022 Earnings Preview
Aug 10Altimmune: Several Catalysts In 2 Large Market Indications This Year
Jun 29Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Altimmune's New Avatar As A Liver Disease Player
Apr 07Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Feb 01Altimmune: Changing Focus To Pemvidutide In 2022
Jan 03Altimmune: Changing The Thesis
Oct 16Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns
Sep 17Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.
Dividend Yield vs Market
| Altimmune Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ALT) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Biotechs) | 2.1% |
| Analyst forecast (ALT) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ALT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALT has not reported any payouts.